EGFR and colorectal carcinoma: The preclinical findings described in our manuscript demonstrated that the antitumor activity obtained by AXL inhibition is clinical relevant, because all human CRC cell lines used do not respond to the common anti-EGFR moAb due to KRAS mutations that confer primary resistance to these agents.